Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Copyright © 2020 Elsevier Ltd. All rights reserved..

The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application.

Media Type:

Electronic Article

Year of Publication:

2020

Contained In:

Journal of autoimmunity - Vol. 111 (2020), p. 102452

Language:

English

Contributors:

Liu, Bingwen
Li, Min
Zhou, Zhiguang
Guan, Xuan
Xiang, Yufei

Links:

Volltext

Keywords:

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
Betacoronavirus
COVID-19
Coronavirus Infections
Coronavirus disease 2019
Cytokine Release Syndrome
Cytokine release syndrome
Humans
I031V2H011
IL6 protein, human
Immunomodulation
Interleukin-6
Journal Article
Pandemics
Pneumonia, Viral
Research Support, Non-U.S. Gov't
Review
SARS-CoV-2
Severe Acute Respiratory Syndrome
Tocilizumab

Notes:

Date Completed 11.06.2020

Date Revised 10.01.2021

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1016/j.jaut.2020.102452

PMID:

32291137

PPN (Catalogue-ID):

NLM309613019